Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9

The small GTPase KRAS is frequently mutated in human cancer and currently there are no targeted therapies for KRAS mutant tumors. Here, we show that the small ubiquitin-like modifier (SUMO) pathway is required for KRAS-driven transformation. RNAi depletion of the SUMO E2 ligase Ubc9 suppresses 3D gr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Proc Natl Acad Sci U S A
Prif Awduron: Yu, Bing, Swatkoski, Stephen, Holly, Alesia, Lee, Liam C., Giroux, Valentin, Lee, Chih-Shia, Hsu, Dennis, Smith, Jordan L., Yuen, Garmen, Yue, Junqiu, Ann, David K., Simpson, R. Mark, Creighton, Chad J., Figg, William D., Gucek, Marjan, Luo, Ji
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: National Academy of Sciences 2015
Pynciau:
PNAS Plus
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394293/
https://ncbi.nlm.nih.gov/pubmed/25805818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1415569112
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg